Metadvice resources

Type 2 diabetes, hypertension, and hypercholesterolemia often develop in tandem with risk factors that appear to be more than additive. This work studies early therapeutic intervention beyond the silos that are created when looking at each morbidity separately.

We tested the hypothesis that machine learning could identify individuals in a UK primary care setting for whom personalised cholesterol-lowering therapy might be more appropriate than guideline-based recommendations.

Metadvice recently presented alongside Lancing & Sompting PCN Clinical Director Dr Shona Schofield at the “Tackling Cholesterol Together Roadshow” hosted by HeartUK and Health Innovation Kent Surrey Sussex…

By Andrew Krentz, 18 March 2024

Defects of insulin secretion and/or action are central to the expanding worldwide pandemic of non-communicable cardiometabolic disorders. In recent decades, large scale human overnutrition has fuelled exploding rates of obesity and type 2 diabetes. Uncommon a century ago, type 2 diabetes now affects around 1 in 10 adults worldwide …

By Andrew Krentz, 21 November 2023

A staggering one-third of the global population may harbour metabolic dysfunction associated fatty liver disease (MAFLD). This burgeoning, obesity-related health crisis is projected to escalate, with obesity rates expected to jump from 15% in 2023 to ~25% by 2035. Metadvice stands at the forefront of this challenge, leveraging AI to empower clinicians in managing the complex web of chronic diseases, particularly where metabolic and cardiovascular disorders intersect. In this blog, we draw on new evidence to explore how Metadvice technology can address this growing disease area.

By Lia Bally, David Herzig, Camillo Piazza, Lucas Brunschwig, Zeina Gabr, Yaron Dibner and André Jaun, 1 July 2023

Combining clinical guidelines with continuous learning from real world evidence data has the potential to effectively implement precision medicine by clinicians caring for people with diabetes. Such AI-driven platforms that integrate data from electronic health records are available and are readily extendable to include data from wearable technologies.

By David Herzig, Lia Bally, Thomas Castiglione, Philippine Des Courtils and André Jaun, 1 July 2023

Continuous glucose monitoring (CGM) provides a wealth of data for diagnostic and therapeutic decision-making in diabetes care. Current clinical treatment guidelines are based on standard time in range statistics. The goal of this study was to build a model, leveraging CGM data only, to characterise glucose-insulin regulation in patients with type 2 diabetes.

By Andrew Krentz, Lucas Brunschwig, Yaron Dibner, Hugo Michel and André Jaun, 18 June 2023

A proof-of-concept analysis that demonstrates the utility of a neural network to predict the development of one or more comorbidities based on data routinely collected in primary care, published in Diabetes, a journal of the American Diabetes Association.

By Metadvice, 23 September 2022

Metadvice is proud to announce that it started a collaboration with the Inselspital (Bern, Switzerland) supported by the Swiss innovation agency (Innosuisse) for a new project entitled: AI Companion for Diabetes Optimisation using Digital Data from Continuous Glucose Monitoring.

By Johnson & Johnson, 29 April 2022

On April 29 – the International Day of Immunology – Johnson & Johnson Innovation, together with Janssen Research & Development, announced that Metadvice and three other companies were awardees of the Immunology Innovations QuickFire Challenge: Precision Medicine in Immune-Mediated Disease.